1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Prostate Cancer Disappointment Means Lilly Might Finally Get The Point

 
• By Elizabeth Cairns

Point Biopharma’s radiopharmaceutical lags Novartis’s on PFS, and its commercial viability may be limited.  

Unhappy and disappointed customer giving low rating and negative feedback in survey, poll or questionnaire. Sad and dissatisfied man giving review about service quality. Bad user experience. - Image

After months of waiting, Eli Lilly and Company might soon get its hands on the radiopharmaceutical specialist POINT Biopharma Global Inc.. In October, Lilly bid $1.4bn to acquire Point, but the majority of the smaller group’s investors declined to tender their shares. It is likely that they wanted to wait for data from the Phase III trial of Point’s prostate cancer radioligand PNT2002; if this were to be a huge success, Point’s shareholders could demand Lilly up its bid.

Key Takeaways
  • The SPLASH trial of Point Biopharma’s radiopharmaceutical PNT2002 yielded disappointing results
  • Its approval chances are lower as a result
  • Point’s shareholders might now feel they have to accept Lilly’s $1

If that was indeed the thinking, the data that came yesterday could change the situation. PNT2002’s SPLASH trial hit, but efficacy was not as strong as had been hoped

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

More from R&D